PPC
GILD icon

Park Place Capital’s Gilead Sciences GILD Stock Holding History

Park Place Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.1K Buy
697
+48
+7% +$6.32K 0.01% 338
2026
Q1 		$90.4K Sell
649
-1,541
-70% -$216K 0.02% 277
2025
Q4 		$269K Sell
2,190
-534
-20% -$64.9K 0.06% 164
2025
Q3 		$302K Sell
2,724
-721
-21% -$82K 0.06% 156
2025
Q2 		$385K Sell
3,445
-2,084
-38% -$222K 0.09% 141
2025
Q1 		$619K Sell
5,529
-1,412
-20% -$146K 0.17% 100
2024
Q4 		$641K Sell
6,941
-1,490
-18% -$134K 0.18% 106
2024
Q3 		$707K Buy
8,431
+1,705
+25% +$130K 0.2% 103
2024
Q2 		$461K Sell
6,726
-1,370
-17% -$91.4K 0.15% 133
2024
Q1 		$593K Buy
8,096
+1,314
+19% +$101K 0.21% 121
2023
Q4 		$549K Sell
6,782
-1,814
-21% -$141K 0.22% 128
2023
Q3 		$644K Sell
8,596
-7,170
-45% -$551K 0.19% 127
2023
Q2 		$1.22M Sell
15,766
-5,903
-27% -$471K 0.34% 62
2023
Q1 		$1.8M Sell
21,669
-7,251
-25% -$601K 0.5% 40
2022
Q4 		$2.48M Buy
+28,920
New +$2.29M 0.7% 28

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Park Place Capital's GILD Position: Q2 2026 in Review

Park Place Capital increased its Gilead Sciences (GILD) stake by 7.4% in Q2 2026, buying an estimated $6.32K and bringing the position to 697 shares worth $88.1K. The position accounts for 0.01% of the portfolio, ranked #338.

Park Place Capital first reported a position in GILD in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.48M in Q4 2022. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Park Place Capital held 697 shares of Gilead Sciences worth $88.1K as of Q2 2026.
  • Park Place Capital bought 48 Gilead Sciences shares in Q2 2026, an estimated $6.32K.
  • Gilead Sciences made up 0.01% of Park Place Capital's portfolio in Q2 2026, its #338 holding.
  • Park Place Capital first reported a position in Gilead Sciences in Q4 2022 and has held it in 15 quarters since.
  • Park Place Capital's Gilead Sciences position peaked at $2.48M in Q4 2022.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.